Developmental pharmacogenetics in pediatric rheumatology: Utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate

Human Genomics and Proteomics

Volumn , Issue , 2010, Pages

  Becker, Mara L ^a   Leeder, J Steven ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; THYMIDYLATE SYNTHASE;

ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; ONTOGENY; PATIENT COMPLIANCE; PEDIATRICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RHEUMATOLOGY;

EID: 77955380631     PISSN: None     EISSN: 17574242     Source Type: Journal    
DOI: 10.4061/2010/257120     Document Type: Article

References (69)

1. Leeder J. S., Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond Drug Discovery Today 2004 9 13 567 573
2. Agunod M., Yamaguchi N., Lopez R., Luhby A. L., Glass G. B. J., Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants The American Journal of Digestive Diseases 1969 14 6 400 414
3. Moazam F., Kirby W. J., Rodgers B. M., McGuigan J. E., Physiology of serum gastrin production in neonates and infants Annals of Surgery 1984 199 4 389 392
4. Gupta M., Brans Y. W., Gastric retention in neonates Pediatrics 1978 62 1 26 29
5. Kearns G. L., Abdel-Rahman S. M., Alander S. W., Blowey D. L., Leeder J. S., Kauffman R. E., Developmental pharmacologydrug disposition, action, and therapy in infants and children New England Journal of Medicine 2003 349 12 1157 1167
6. Hines R. N., The ontogeny of drug metabolism enzymes and implications for adverse drug events Pharmacology and Therapeutics 2008 118 2 250 267
7. Johnson T. R., Moore W. M., Jeffries J. E., Children are Different: Developmental Physiology 1978 2nd Columbus, Ohio, USA Ross laboratories
8. Leeder J. S., Pearce R. E., Gaedigk A., Modak A., Rosen D. I., Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype Journal of Clinical Pharmacology 2008 48 9 1041 1051
9. Leeder J. S., Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology Clinical Pharmacology and Therapeutics 2009 86 6 678 682
10. Leeder J. S., Kearns G. L., Spielberg S. P., van den Anker J., Understanding the Relative Roles of Pharmacogenetics and Ontogeny in Pediatric Drug Development and Regulatory Science Journal of Clinical Pharmacology. E pub Feb 11, 2010
11. Cassidy J. T., Petty R. E., Laxer R. M., Textbook of Pediatric Rheumatology 2005 5th Philadelphia, Pa, USA Saunders
12. Prahalad S., Glass D. N., A comprehensive review of the genetics of juvenile idiopathic arthritis Pediatric Rheumatology 2008 6, article no. 11
13. Griffin T. A., Barnes M. G., Ilowite N. T., Olson J. C., Sherry D. D., Gottlieb B. S., Aronow B. J., Pavlidis P., Hinze C. H., Thornton S., Thompson S. D., Grom A. A., Colbert R. A., Glass D. N., Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets Arthritis and Rheumatism 2009 60 7 2113 2123
14. Barnes M. G., Grom A. A., Thompson S. D., Griffin T. A., Pavlidis P., Itert L., Fall N., Sowders D. P., Hinze C. H., Aronow B. J., Luyrink L. K., Srivastava S., Ilowite N. T., Gottlieb B. S., Olson J. C., Sherry D. D., Glass D. N., Colbert R. A., Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis Arthritis and Rheumatism 2009 60 7 2102 2112
15. Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A.-M., Suarez-Almazor M. E., Woo P., International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 Journal of Rheumatology 2004 31 2 390 392
16. Truckenbrodt H., Hafner R., Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study Arthritis and Rheumatism 1986 29 6 801 807
17. Speckmaier M., Findeisen J., Woo P., Hall A., Sills J. A., Pric e T., Hollingworth P., Craft A., Ansell B. M., Low-dose methotrexate in systemic onset juvenile chronic arthritis Clinical and Experimental Rheumatology 1989 7 6 647 650
18. Wallace C. A., Sherry D. D., Mellins E. D., Aiken R. P., Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment Journal of Rheumatology 1993 20 1 118 122
19. Rose C. D., Singsen B. H., Eichenfield A. H., Goldsmith D. P., Athreya B. H., Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis Journal of Pediatrics 1990 117 4 653 659
20. Halle F., Prieur A. M., Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype Clinical and Experimental Rheumatology 1991 9 3 297 302
21. Giannini E. H., Brewer E. J., Kuzmina N., Shaikov A., Maximo A., Vorontson I., Fink C. W., Newman A. J., Cassidy J. T., Zemel L. S., Methotrexate in resistant juvenile rheumatoid arthritisresults of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial New England Journal of Medicine 1992 326 16 1043 1049
22. Ruperto N., Murray K. J., Gerloni V., Wulffraat N., De Oliveira S. K. F., Falcini F., Dolezalova P., Alessio M., Burgos-Vargas R., Corona F., Vesely R., Foster H., Davidson J., Zulian F., Asplin L., Baildam E., Consuegra J. G., Ozdogan H., Saurenmann R., Joos R., Pistorio A., Woo P., Martini A., A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate Arthritis and Rheumatism 2004 50 7 2191 2201
23. Lambert C. M., Sandhu S., Lochhead A., Hurst N. P., McRorie E., Dhillon V., Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial Arthritis and Rheumatism 2004 50 2 364 371
24. Cohen S., Cannon G. W., Schiff M., Weaver A., Fox R., Olsen N., Furst D., Sharp J., Moreland L., Caldwell J., Kaine J., Strand V., Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate Arthritis and Rheumatism 2001 44 9 1984 1992
25. Lafforgue P., Monjanel-Mouterde S., Durand A., Catalin J., Acquaviva P.-C., Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis Journal of Rheumatology 1995 22 5 844 849
26. Ravelli A., Di Fuccia G., Molinaro M., Ramenghi B., Zonta L., Regazzi M. B., Martini A., Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis Journal of Rheumatology 1993 20 9 1573 1577
27. Albertioni F., Flato B., Seideman P., Beck O., Vinje O., Peterson C., Eksborg S., Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics European Journal of Clinical Pharmacology 1995 47 6 507 511
28. Matherly L. H., Goldman I. D., Membrane transport of folates Vitamins and Hormones 2003 66 403 456
29. Chabner B. A., Allegra C. J., Curt G. A., Polyglutamation of methotrexate. Is Methotrexate a prodrug? Journal of Clinical Investigation 1985 76 3 907 912
30. Allegra C. J., Chabner B. A., Drake J. C., Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates Journal of Biological Chemistry 1985 260 17 9720 9726
31. Schroder H., Fogh K., Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia Cancer Chemotherapy and Pharmacology 1988 21 2 145 149
32. Cronstein B. N., Naime D., Ostad E., The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation Journal of Clinical Investigation 1993 92 6 2675 2682
33. Dervieux T., Furst D., Lein D. O., Capps R., Smith K., Walsh M., Kremer J., Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis Arthritis and Rheumatism 2004 50 9 2766 2774
34. Herbert V., Making sense of laboratory tests of folate status: folate requirements to sustain normality American Journal of Hematology 1987 26 2 199 207
35. Ifergan I., Shafran A., Jansen G., Hooijberg J. H., Scheffer G. L., Assaraf Y. G., Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression: a role for BCRP in cellular folate homeostasis Journal of Biological Chemistry 2004 279 24 25527 25534
36. Dervieux T., Furst D., Lein D. O., Capps R., Smith K., Caldwell J., Kremer J., Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study Annals of the Rheumatic Diseases 2005 64 8 1180 1185
37. Dervieux T., Kremer J., Lein D. O., Capps R., Barham R., Meyer G., Smith K., Caldwell J., Furst D. E., Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis Pharmacogenetics 2004 14 11 733 739
38. Dervieux T., Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis Pharmacogenet Genomics 2009 19 12 935 944
39. Dolealov P., Krijt J., Chldek J., Nmcov D., Hoza J., Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis Rheumatology 2005 44 1 74 79
40. Baggott J. E., Vaughn W. H., Hudson B. B., Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′ -adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide Biochemical Journal 1986 236 1 193 200
41. Becker M. L., Van Haandel L., Gaedigk R., Lasky A., Hoeltzel M., Stobaugh J., Steven Leeder J., Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations Arthritis and Rheumatism 2010 62 6 1803 1812
42. Becker M. L., Gaedigk R., van Haandel L., Stobaugh J., Leeder J. S., Clinical and genetic predictors of methotrexate polyglutamate patterns in JIA Clinical Pharmacology and Therapeutics 87. supplement 1, S68, 2010
43. Wessels J. A. M., De Vries-Bouwstra J. K., Heijmans B. T., Slagboom P. E., Goekoop-Ruiterman Y. P. M., Allaart C. F., Kerstens P. J. S. M., Van Zeben D., Breedveld F. C., Bijkmans B. A. C., Huizinga T. W. J., Guchelaar H.-J., Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes Arthritis and Rheumatism 2006 54 4 1087 1095
44. van der Straaten R. J. H. M., Wessels J. A. M., de Vries-Bouwstra J. K., Goekoop-Ruiterman Y. P. M., Allaart C. F., Bogaartz J., Tiller M., Huizinga T. W. J., Guchelaar H.-J., Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients Pharmacogenomics 2007 8 2 141 150
45. Volk E. L., Schneider E., Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter Cancer Research 2003 63 17 5538 5543
46. Van Ede A. E., Laan R. F. J. M., Blom H. J., Huizinga T. W. J., Haagsma C. J., Giesendorf B. A. J., De Boo T. M., Van De Putte L. B. A., The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients Arthritis and Rheumatism 2001 44 11 2525 2530
47. Berkun Y., Levartovsky D., Rubinow A., Orbach H., Aamar S., Grenader T., Abou Atta I., Mevorach D., Friedman G., Ben-Yehuda A., Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene Annals of the Rheumatic Diseases 2004 63 10 1227 1231
48. Schmeling H., Biber D., Heins S., Horneff G., Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis Journal of Rheumatology 2005 32 9 1832 1836
49. Patio-Garca A., Zalacan M., Marrodn L., San-Julin M., Sierrasesmaga L., Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression Journal of Pediatrics 2009 154 5 688 693
50. Dervieux T., Greenstein N., Kremer J., Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis Arthritis and Rheumatism 2006 54 10 3095 3103
51. Wessels J. A. M., Kooloos W. M., De Jonge R., De Vries-Bouwstra J. K., Allaart C. F., Linssen A., Collee G., De Sonnaville P., Lindemans J., Huizinga T. W. J., Guchelaar H.-J., Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis Arthritis and Rheumatism 2006 54 9 2830 2839
52. Hinks A., Halima M., Martin P., Genetic polymorphisms in key methotrexate pathway genes associated with response to MTX treatment in juvenile idiopathic arthritis Arthritis and Rheumatism 2009 60 supplement 10 S233
53. Hider S. L., Thomson W., Mack L. F., Armstrong D. J., Shadforth M., Bruce I. N., Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX Rheumatology 2008 47 8 1156 1159
54. Ranganathan P., An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents Current Opinion in Molecular Therapeutics 2008 10 6 562 567
55. Weisman M., Furst D., Park G., Risk genotypes in folate-dependent enzymes profile rheumatoid arthritis patients with side effects to methotrexate therapy Arthritis and Rheumatism 2005 52, supplement 1950
56. Oostendorp R. L., Beijnen J. H., Schellens J. H. M., The biological and clinical role of drug transporters at the intestinal barrier Cancer Treatment Reviews 2009 35 2 137 147
57. Zhao R., Matherly L. H., Goldman I. D., Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues Expert Reviews in Molecular Medicine 2009 11 e4
58. Qiu A., Jansen M., Sakaris A., Min S. H., Chattopadhyay S., Tsai E., Sandoval C., Zhao R., Akabas M. H., Goldman I. D., Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption Cell 2006 127 5 917 928
59. Vlaming M. L., Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo Molecular Cancer Therapeutics 2009 8 12 3350 3359
60. Yuasa H., Inoue K., Hayashi Y., Molecular and functional characteristics of proton-coupled folate transporter Journal of Pharmaceutical Sciences 2009 98 5 1608 1616
61. Liu M., Ge Y., Cabelof D. C., Aboukameel A., Heydari A. R., Mohammad R., Matherly L. H., Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates Journal of Biological Chemistry 2005 280 7 5588 5597
62. Kato S., Ito K., Kato Y., Wakayama T., Kubo Y., Iseki S., Tsuji A., Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate Pharmaceutical Research 2009 26 6 1467 1476
63. Rau T., Erney B., Gres R., Eschenhagen T., Beck J., Langer T., High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations Clinical Pharmacology and Therapeutics 2006 80 5 468 476
64. Ranganathan P., Culverhouse R., Marsh S., Mody A., Scott-Horton T. J., Brasington R., Joseph A., Reddy V., Eisen S., McLeod H. L., Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in caucasian and african american patients with rheumatoid arthritis Journal of Rheumatology 2008 35 4 572 579
65. Takatori R., Takahashi K. A., Tokunaga D., Hojo T., Fujioka M., Asano T., Hirata T., Kawahito Y., Satomi Y., Nishino H., Tanaka T., Hirota Y., Kubo T., ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients Clinical and Experimental Rheumatology 2006 24 5 546 554
66. Niemi M., Transporter pharmacogenetics and statin toxicity Clinical Pharmacology and Therapeutics 2009 87 1 130 133
67. Trevino L. R., Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects Journal of Clinical Oncology 2009 27 35 5972 5978
68. Abe T., Unno M., Onogawa T., Tokui T., Noriko Kondo T., Nakagomi R., Adachi H., Fujiwara K., Okabe M., Suzuki T., Nunoki K., Sato E., Kakyo M., Nishio T., Sugita J., Asano N., Tanemoto M., Seki M., Date F., Ono K., Kondo Y., Shiiba K., Suzuki M., Ohtani H., Shimosegawa T., Iinuma K., Nagura H., Ito S., Matsuno S., LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers Gastroenterology 2001 120 7 1689 1699
69. Masuda M., I'izuka Y., Yamazaki M., Nishigaki R., Kato Y., Ni'inuma K., Suzuki H., Sugiyama Y., Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats Cancer Research 1997 57 16 3506 3510 (Pubitemid 27355499)